NRx Completes Ketamine Manufacturing Validation Ahead of November FDA Review Target

Key Points

• NRx Pharmaceuticals completed three commercial-scale validation lots of its preservative-free ketamine.
• Two-year room-temperature testing showed no deterioration in purity, potency or sterility, according to the company.
• NRx believes the findings could support a shelf life of three years or longer, but that duration has not yet been demonstrated by the reported real-time data.
• Supply is on hand for potential commercial release, pending FDA approval.
• The company’s generic drug application has a November 10, 2026, FDA review goal date—not a guaranteed approval date.

NRx Pharmaceuticals (NASDAQ: NRXP) has completed manufacturing process validation for its preservative-free ketamine, moving the product closer to potential commercial supply ahead of its November FDA review target.

The company said three lots were successfully produced under commercial conditions with manufacturing partner Nephron Pharmaceuticals in West Columbia, South Carolina.

Commercial-Scale Production Supports Launch Readiness

The validation work is intended to demonstrate that the manufacturing process can consistently produce the drug in compliance with FDA Good Manufacturing Practices.

NRx says it now has supply on hand that could be released commercially if the FDA approves its Abbreviated New Drug Application, or ANDA. The company plans to supply hospitals and clinics with a product it describes as being in shortage.

Completing manufacturing validation does not itself authorize sales.

Two-Year Testing Shows Room-Temperature Stability

NRx reported that real-time testing over two years found no deterioration in the drug’s purity, potency or sterility without preservatives.

The company believes those findings are consistent with a potential labeled shelf life of three years or longer. However, the data announced cover two years; a longer shelf life remains a projection rather than a demonstrated result from that testing period.

November 10 Is the Next Regulatory Milestone

The FDA review goal date for the application is November 10, 2026. NRx says its manufacturing progress positions it to begin supplying the product following approval.

The announcement does not include an FDA approval, a confirmed launch date, pricing or expected sales.

Investor Takeaway: Supply Preparation Advances, but Approval Remains Pending

For NRXP investors, the update addresses two important elements of commercial readiness: consistent manufacturing and product stability.

The central milestone remains the FDA’s decision on the application. Having inventory available could support a launch following approval, but it does not guarantee approval or establish the product’s financial contribution.